Grand Rounds: Individualizing Diagnosis and Therapy for IBS April 11, 2014 Overview Show transcript Overview Arthur Beyder, M.D., Ph.D., and Gianrico Farrugia, M.D., discuss the morbidity, pathophysiology and genetics of irritable bowel syndrome (IBS), a complex genetic disease. In some cases, IBS is an ion channelopathy. Drs. Beyder and Farrugia discuss the involvement of SCN5A and NaV1.5 mutations in patients with IBS. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleCurrent and future treatments for irritable bowel syndrome associated with diarrheaArticleUpdate on IBS treatments: Examining the efficacy of antidepressants, psychological therapies, prebiotics, probiotics, synbiotics and antibioticsArticleUnderstanding the role of proteolytic activity in mediating irritable bowel syndrome symptoms and disruption of intestinal barrier function VID-20433422 Medical Professionals Grand Rounds: Individualizing Diagnosis and Therapy for IBS